Publications by authors named "A A Brandes"
Background: Screening for atrial fibrillation is rising and may worsen or improve quality of life.
Methods: We assessed quality of life (EQ-5D-5L) data in 6,004 participants with stroke risk factors randomised to usual care (n=4,503) or implantable loop recorder with anticoagulation upon detection of atrial fibrillation (n=1,501). Five domains (mobility, selfcare, usual activities, pain/discomfort, anxiety/depression) each scored from one to five were calculated into individual index scores (worst=-0.
Article Synopsis
- Clinical atrial fibrillation (AF) significantly raises the risk of stroke and systemic embolism, but treatment with oral anticoagulants can lower this risk while increasing the chance of major bleeding.
- Device-detected atrial fibrillation (DDAF) also poses a stroke risk, though lower than clinical AF, with studies showing that direct oral anticoagulation can reduce stroke risk for DDAF patients but similarly heightens bleeding risk.
- The challenge persists in determining how to effectively manage the balance between reducing thromboembolic risk and the increased risk of bleeding for DDAF patients, as well as identifying those who would benefit most from anticoagulant therapy.
Background: Approximately 30% of patients with atrial fibrillation suffer from depression. Depression in patients with atrial fibrillation is associated with poor health outcomes, reduced health-related quality of life, and elevated societal costs. Preventing depression in this population may therefore lead to better health outcomes for the individual patient and reduced burden on society.
View Article and Find Full Text PDFBackground: Clinically important perioperative atrial fibrillation (POAF) is a common cardiac complication after noncardiac surgery. Little is known about how patients with POAF are managed acutely and whether practices have changed over time.
Methods: We conducted an observational substudy of patients who had POAF, were at elevated cardiovascular risk, and were enrolled in the PeriOperative Ischemic Evaluation (POISE)-1, 2 and 3 trials between 2002 and 2021.
Article Synopsis
- Accurate grading of IDH-mutant gliomas is crucial for predicting patient outcomes and selecting treatment strategies, yet histological grading remains difficult, with limited molecular markers available.
- Researchers performed RNA-sequencing on 138 IDH-mutant astrocytomas from the CATNON trial and analyzed multi-omics data to create a Continuous Grading Coefficient (CGC), which proved to be a better survival predictor than current grading systems.
- The study identified four distinct transcriptional clusters linked to various gene expression patterns, revealing that higher-grade IDH-mutant astrocytomas exhibit DNA-methylation signatures correlated with increased cell cycling, tumor de-differentiation, and changes in the extracellular matrix.